Celator® Pharmaceuticals to Present Data at the 56th American Society of Hematology Annual Meeting

EWING, N.J., Nov. 24, 2014 /PRNewswire/ -- Celator Pharmaceuticals, Inc. (Nasdaq: CPXX), a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today announced that data for CPX-351, its lead product candidate, will be presented at the 56^th American Society of Hematology (ASH) Annual Meeting and Exposition in San Francisco, December 6-9, 2014.

Abstracts submitted by Celator and selected for poster presentation will provide insight into the potential advantages of CPX-351's pharmacokinetics with regard to renal/hepatic impairment, exposure to healthy tissues, and enhanced drug delivery to bone marrow:

These posters will be available on Celator's website (www.celatorpharma.com).

CPX-351 is being studied in a number of investigator-initiated studies.  An abstract was submitted by an investigator for an ongoing study, based on interim data, and was selected for poster presentation:

Investor Reception Information

Celator will host an investor reception on Saturday, December 6, 2014, beginning at 7:30 p.m. PST (10:30 p.m. EST) in San Francisco to provide a corporate update and review data. The event will feature guest speaker, Jeffrey Lancet, MD, Senior Member and Chief of the Leukemia/Myelodysplasia Program at Moffitt Cancer Center.

About Celator Pharmaceuticals, Inc.

Celator Pharmaceuticals, Inc., with locations in Ewing, N.J., and Vancouver, B.C., is a clinical stage biopharmaceutical company that is transforming the science of combination therapy, and developing products to improve patient outcomes in cancer. Celator's proprietary technology platform, CombiPlex®, enables the rational design and rapid evaluation of optimized combinations incorporating traditional chemotherapies as well as molecularly targeted agents to deliver enhanced anti-cancer activity.  CombiPlex addresses several fundamental shortcomings of conventional combination regimens, as well as the challenges inherent in combination drug development, by identifying the most effective synergistic molar ratio of the drugs being combined in vitro, and fixing this ratio in a nano-scale drug delivery complex to maintain the optimized combination until exposure to the tumor following administration.  Celator's pipeline includes lead product, CPX-351 (a liposomal formulation of cytarabine:daunorubicin) for the treatment of acute myeloid leukemia; CPX-1 (a liposomal formulation of irinotecan:floxuridine) for the treatment of colorectal cancer; a preclinical stage product candidate, CPX-8 (a hydrophobic docetaxel prodrug nanoparticle formulation), being studied by the National Cancer Institute's Nanotechnology Characterization Laboratory; and several programs exploring novel combinations of existing drugs, including molecularly targeted therapies.

For more information, please visit Celator's website at www.celatorpharma.com. Information on ongoing trials is available at www.clinicaltrials.gov.

Forward-Looking Statements:

To the extent that statements contained in this press release are not descriptions of historical facts regarding Celator, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "anticipate," "believe," "estimate," "intend," and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Examples of forward-looking statements contained in this press release include, among others, statements regarding the safety, efficacy and therapeutic potential of CPX-351, our expectations regarding our research and development programs, and expanding our pipeline and advancing our CombiPlex platform.  Forward-looking statements in this release involve substantial risks and uncertainties that could cause our preclinical and clinical development programs and other future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the conduct of ongoing and future clinical studies and other matters that could affect the commercial potential of our drug candidates.  Celator undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the company in general, see Celator's Form 10-K for the year ended December 31, 2013 and other filings by the company with the U.S. Securities and Exchange Commission.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/celator-pharmaceuticals-to-present-data-at-the-56th-american-society-of-hematology-annual-meeting-300000066.html

SOURCE Celator Pharmaceuticals, Inc.

Related Links

http://www.celatorpharma.com